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Mitochondria are emerging as important players in the transfor-
mation process of cells, maintaining the biosynthetic and energetic
capacities of cancer cells and serving as one of the primary sites of
apoptosis and autophagy regulation. Although several avenues of
cancer therapy have focused on mitochondria, progress in devel-
oping mitochondria-targeting anticancer drugs nonetheless has
been slow, owing to the limited number of known mitochondrial
target proteins that link metabolism with autophagy or cell death.
Recent studies have demonstrated that two members of the newly
discovered family of NEET proteins, NAF-1 (CISD2) and mitoNEET
(mNT; CISD1), could play such a role in cancer cells. NAF-1 was
shown to be a key player in regulating autophagy, and mNT
was proposed to mediate iron and reactive oxygen homeostasis
in mitochondria. Here we show that the protein levels of NAF-1
and mNT are elevated in human epithelial breast cancer cells, and
that suppressing the level of these proteins using shRNA results in
signiﬁcantly reduced cell proliferation and tumor growth, de-
creased mitochondrial performance, uncontrolled accumulation
of iron and reactive oxygen in mitochondria, and activation of
autophagy. Our ﬁndings highlight NEET proteins as promising mi-
tochondrial targets for cancer therapy.
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Mitochondria play a key role in many human diseases relatedto their functions in cellular energy production, bio-
synthesis of essential cellular compounds, and involvement in
autophagy and/or apoptosis regulation (1). Contrary to pre-
viously held beliefs, recent studies have demonstrated that mi-
tochondria are also key players in the transformation process of
cancer cells and may be used as targets for anticancer therapy
(2–6). The involvement of mitochondria in cancer cell function
could be linked to the enhanced accumulation of iron and re-
active oxygen species (ROS) in mitochondria of cancer cells,
which is thought to result from the increased metabolic and
energetic demands of the transformed phenotype (7). An in-
teresting, recently discovered group of proteins that could link
iron and ROS homeostasis with mitochondrial function in cancer
cells are NEET proteins (8–15).
NEET proteins [mitoNEET (mNT; CISD1), Nutrient-depri-
vation autophagy factor-1 (NAF-1; CISD2), and CISD3] are
a class of iron-sulfur proteins involved in several human pa-
thologies, including diabetes, cystic ﬁbrosis, Wolfram syndrome
2, neurodegeneration, and muscle atrophy (16–22). mNT and
NAF-1 are localized to the outer mitochondrial membrane.
NAF-1 is also localized to the endoplasmic reticulum, where it
interacts with BCL-2 and Beclin 1 to regulate autophagy and
apoptosis (8–13). Deﬁciency in mNT causes the accumulation of
iron and ROS in mitochondria of animal and plant cells, and
deﬁciency in NAF-1 results in decreased mitochondrial function
and stability, as well as activation of autophagy in mice and
human cells (13–16, 20, 21).
Interestingly, levels of mNT and NAF-1 mRNA are increased
signiﬁcantly in many different human cancer cells (23–25). The
involvement of NAF-1 and mNT in mitochondrial metabolism
and homeostasis, as well as in autophagy regulation, points to
a possible role for these proteins in cell transformation. Thus, we
hypothesized that suppressing the expression of these proteins
could inhibit cancer proliferation. To address this hypothesis, we
studied the regulation and function of NAF-1 and mNT in hu-
man epithelial breast cancer cells (MCF-7 and MDA-231) and,
in particular, how controlling the expression level of these pro-
teins affects tumor growth.
Here we report that NAF-1 and mNT protein levels accu-
mulate in human epithelial breast cancer cells, and that suppress-
ing the level of these proteins in cancer cells results in signiﬁcantly
reduced cell proliferation and tumor growth, decreased mi-
tochondrial performance, uncontrolled accumulation of iron and
ROS in mitochondria, and activation of autophagy. Taken to-
gether, our ﬁndings indicate that NEET proteins may be prom-
ising mitochondrial targets for cancer therapy.
Results
Accumulation of NEET Proteins and Mitochondrial Function in Human
Epithelial Breast Cancer Cells. Protein blot analysis of NAF-1 and
mNT in three different human epithelial breast cancer cell lines
(MCF-7, MDA-MB-468, and HCC-70, compared with control
breast MCF-10a cells) revealed signiﬁcantly elevated NAF-1 levels
in all three lines, and signiﬁcantly elevated mNT levels in two of
these lines (Fig. 1A). These ﬁndings are supported by mRNA
expression studies of NEET proteins in breast cancer cells (23–
25), and suggest a role for NEET proteins in promoting mito-
chondrial biogenesis and autophagy resistance in cancer cells (23).
Suppression of mNT (mNT−) or NAF-1 (NAF-1−) protein
levels using shRNA in MCF-7 and MDA-231 cells (Fig. 1B and
Fig. S1) caused a signiﬁcant decrease in cell proliferation (Fig.
1C and Figs. S2 and S3). Suppression of mNT or NAF-1 in MCF-7
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cells also resulted in diminished spare respiratory capacity of mi-
tochondria and enhanced glycolytic activity, as calculated based on
the oxygen consumption rate (OCR), which is an indicator of
mitochondrial respiration, and the acid efﬂux rate (ECAR),
which is predominantly a measure of lactic acid formed during
glycolytic energy metabolism (Fig. 1 D and E). In contrast, over-
expression of mNT orNAF-1 led to an increased spare respiratory
capacity of mitochondria and decreased glycolytic activity (Fig.
S4). These results demonstrate a physiological role for mNT and
NAF-1 in promoting mitochondrial function in cancer cells.
Accumulation of Iron and ROS in Mitochondria of Human Epithelial
Breast Cells with Suppressed Expression of NEET Proteins. NAF-1
and mNT function as iron-cluster transfer proteins, and mNT is
responsible for iron homeostasis in mitochondria (10, 11, 14, 15,
18, 19). Maintaining a balanced iron level in mitochondria is
necessary to maintain mitochondrial membrane potential and
regulation of mitochondrial ROS levels. To examine the mech-
anism of mNT and NAF-1 function in cancer cells, we measured
mitochondrial membrane potential, mitochondrial iron accumu-
lation, and mitochondrial ROS levels in epithelial human breast
cancer cells with suppressed levels of NAF-1 or mNT. Suppres-
sion of mNT or NAF-1 expression in breast cancer cells resulted in
decreased mitochondrial membrane potential (Fig. 2A and Fig.
S5), as indicated by decreased ﬂuorescence of tetramethylrhod-
amine ethyl ester (TMRE), a positively charged red-orange dye
that readily accumulates in active mitochondria owing to their
relative negative charge; increased mitochondrial iron levels
(Fig. 2B and Fig. S5), as evidenced by the iron-derived quenching
of rhodamine B-[(1,10-phenanthrolin-5-yl aminocarbonyl] benzyl
ester (RPA) ﬂuorescence in mitochondria; and increased mito-
chondrial ROS accumulation (Fig. 2C), as evidenced by the in-
creased ﬂuorescence of dehydroetidium (DHE) on interaction
with superoxide radicals. The overaccumulation of iron and
ROS, along with the decrease in mitochondrial membrane po-
tential, in cells with suppressed mNT or NAF-1 were blocked by
the addition of the iron chelator deferiprone (DFP) (Fig. 2 A–C
and Fig. S5), demonstrating that the accumulation of ROS and
the decrease in mitochondrial membrane potential in breast cancer
cells with disrupted levels of mNT or NAF-1 is a result of impaired
iron homeostasis caused by the deﬁciency in NEET proteins.
Activation of Autophagy in Human Epithelial Breast Cells with
Suppressed Expression of NEET Proteins. Accumulation of ROS in
mitochondria is a known trigger of autophagy resulting in the
removal of damaged mitochondria (26). To examine the degree
of mitochondrial damage and the activation of autophagy in
breast cancer cells with suppressed mNT or NAF-1 expression
Fig. 1. Protein expression, cellular proliferation and mitochondrial function of mNT and NAF-1 in human epithelial breast cancer cells. (A) Accumulation of mNT
and NAF-1 protein in three different human epithelial breast cancer cell lines. (B) Suppression of mNT and NAF-1 protein expression in MCF-7 cells expressing shRNA
against mNT (mNT−) or NAF-1 (NAF-1−). (Upper) Protein blot. (Lower) Relative levels of the respective proteins. (C) Suppression of cell growth and proliferation in
mNT− or NAF-1−MCF-7 cells. (Inset) Relative change in growth rate for control, mNT(−), and NAF-1(−) at day 6. (D) Mitochondrial function (Left) and glycolytic activity
(Right) in control MCF-7 cells and MCF-7 cells expressing shRNA against mNT (mNT−) or NAF-1 (NAF-1−). (E) Spare respiratory capacity (Left) and glycolytic capacity
(Right) in control and mNT− or NAF-1− MCF-7 cells. NAF-1 and mNT are seen to accumulate in breast cancer cells, and their suppression via shRNA results in sup-
pressed cell proliferation and reduced mitochondrial function. Figs. S1, S2, and S3 present similar results with MDA-231 cells. *P < 0.05; **P < 0.01.
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we conducted a TEM study of these cells. Human epithelial breast
cancer cells with suppressed levels of mNT or NAF-1 accu-
mulated damaged mitochondria with an elongated shape, many
of which contained no crista (Fig. 3B). In addition, these cells
contained high levels of autophagosomes (Fig. 3B), but did not
display apoptotic bodies.
To further conﬁrm the activation of autophagy in mNT− or
NAF-1−MCF-7 cells (Fig. 3 A and B), we performed protein blot
analysis of control MCF-7 and mNT− or NAF-1− MCF-7 cells,
following the level of known molecular markers of autophagy.
Protein gels of total protein (Fig. 3C) and protein blots (Fig. 3D)
of control MCF-7 and mNT− or NAF-1− cells indicate that com-
pared with control MCF-7 cells, the level of many known protein
markers for autophagy, including Atg3, Atg5, Atg12, and Lc3B,
accumulate in mNT− and NAF-1− MCF-7 cells (representative
blots are shown from two independent experiments; the arrow in
the Lc3B panel indicates the autophagy-associated form).
Suppressed Growth of Tumors with Altered Expression of NEET Proteins.
Impaired mitochondrial function and activation of autophagy in
human breast cancer cells with suppressed expression of NEET
proteins (Figs. 1D, 2, and 3) resulted in suppressed proliferation of
cells growing in cell culture medium (Figs. 1C and 4A and Figs. S2
and S3). Although these conditions could be similar to some of the
conditions seen in early phases of cancer development, tumor for-
mation and the various processes involved in tumor establishment
differ greatly from processes seen in cells growing in culture.
To examine the effect of mNT or NAF-1 deﬁciency on tumor
growth, we s.c. injected control MDA-231 cells and MDA-231
cells with suppressed expression of mNT or NAF-1 in nude mice
and followed the rate of tumor growth. Compared with the mice
injected with control MDA-231 cells, tumor size (Fig. 4A) and
growth (Fig. 4 B–D) were signiﬁcantly reduced in the mice
injected with MDA-231 cells with suppressed mNT or NAF-1
expression. Along with their smaller size (Fig. 4 A–D), tumors
from mNT− and NAF-1− MDA-231 cells were more homoge-
neous in their structure and did not contain a necrotic center
(Fig. 4E). These results demonstrate that mNT and NAF-1 are
important not only for the proliferation of cancer cells, but also
for the development and growth of tumors.
Discussion
Our ﬁndings demonstrate that mNT and NAF-1 are required for
human epithelial breast cancer cell proliferation and tumor
growth. Interestingly, mNT and NAF-1 do not complement each
other in the support of breast cancer cell proliferation or tumor
Fig. 2. Decreased membrane potential and overaccumulation of iron and
ROS in mitochondria of cells with suppressed expression of mNT or NAF-1.
(A) Images (Left) and a quantitative graph (Right) showing decreased mi-
tochondrial membrane potential in cells with suppressed expression of mNT
(mNT−) or NAF-1 (NAF-1−). Pretreatment of cells with the iron chelator DFP (50
μM) prevents the decrease in mitochondrial membrane potential (Right). (B)
Images (Left) and a quantitative graph (Right) showing overaccumulation of
iron in mitochondria of mNT− or NAF-1− cells. Pretreatment of cells with the
iron chelator DFP (100 μM) prevents mitochondrial iron accumulation (Right).
(C) Images (Upper Left), a time course (Lower Left), and a quantitative graph
(Right) showing the accumulation of ROS in mitochondria of mNT− or NAF-1−
cells. Pretreatment of cells with the iron chelator DFP (100 μM) prevents mi-
tochondrial ROS accumulation (Right). The function of mNT and NAF-1 is seen
to be required for maintaining mitochondrial membrane potential, as well as
mitochondrial iron and ROS homeostasis in human epithelial breast cancer
cells. Fig. S5 presents similar results with MDA-231 cells. *P < 0.05, **P < 0.01.
Fig. 3. Activation of autophagy in human epithelial breast cancer cells with
suppressed expression of mNT or NAF-1. (A) Three representative trans-
mission electron microscopy (TEM) images of mitochondria from control
cancer cells (Left) and cancer cells with suppressed expression of mNT (mNT−;
Center) or NAF-1 (NAF-1−; Right). (B) Quantitative analysis of mitochondrial
damage in the form of loss of crista (Top), abnormal elongation (Middle), and
the accumulation of autophagosomes (Bottom) in TEM images from control
and mNT− or NAF-1− cells. (C and D) Protein gel analysis (C) and protein blot
analysis (D) showing accumulation of autophagy marker proteins in breast
cancer cells with suppressed expression of mNT (mNT−) or NAF-1 (NAF-1−).
Autophagy is shown to be activated in human epithelial breast cancer cells
with suppressed expression of mNT or NAF-1. The arrow indicates the position
of Lc3B. *P < 0.05.
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growth (Figs. 1 and 4), and likely function via noncomplementary
cellular routes. Deﬁciency in either mNT or NAF-1 disrupts
mitochondrial function and enhances the accumulation of iron
and ROS in mitochondria (Figs. 2 and 3), demonstrating that
both proteins are required for maintenance of mitochondrial
integrity, as well as iron and ROS homeostasis in cells. More-
over, deﬁciency in NAF-1 or mNT activates autophagy (Fig. 3),
demonstrating that both proteins trigger a common downstream
pathway in cancer cells. Thus, we propose that mNT and NAF-1
have similar, albeit noncomplementary, functions in breast can-
cer cells to support mitochondrial metabolism and maintain
mitochondrial iron and ROS homeostasis. Although artiﬁcial
overexpression of mNT has been suggested to trigger autophagy
resistance in human breast cancer cells (23), the naturally oc-
curring high levels of mNT protein found in the MCF-7 human
breast cancer cell line (Fig. 1A) could not mitigate the activation
of autophagy by NAF-1 deﬁciency (Fig. 3). On the other hand,
NAF-1 has been proposed to interact with BCL-2 and Beclin-1
and suppress autophagy (12, 13). Nevertheless, the naturally
occurring high levels of NAF-1 found in the different human
breast cancer cell lines (Fig. 1A) could not mitigate the activation
of autophagy by mNT deﬁciency (Fig. 3). These results could
suggest that, at least in epithelial breast cancer cells, the function
of mNT and NAF-1 in maintaining a balanced iron and ROS
homeostasis outweighs their proposed function in autophagy or
cell death regulation.
Our results demonstrate that mitochondrial function is es-
sential for cancer cell proliferation and tumor growth. Only when
mitochondrial function was suppressed in breast cancer cells as
a result of mNT or NAF-1 deﬁciency did cancer cells turn to
glycolysis for energy production (Fig. 1 D and E). The de-
pendency of cancer cells on mitochondria, as well as on mNT or
NAF-1 function, suggest that these proteins could be used as
important targets for anticancer therapy. In this context, it is
important to note that long-term treatment of diabetic patients
with pioglitazone, a drug that binds NEET proteins and stabilizes
their iron-sulfur clusters, reduces the occurrence of breast, co-
lorectal, and liver cancers compared with placebo, with some
conﬂicting reports on its effect on bladder cancer (27–29). Pio-
glitazone also proved effective in reducing the proliferation of
human breast cancer cells grown in tissue culture (Fig. S6).
These ﬁndings are also consistent with several clinical studies
showing that the weak mitochondrial poison metformin decrea-
ses the onset of many different types of human cancers in di-
abetic patients (23, 30). Thus, mitochondria, NAF-1, and mNT
should be considered as potential targets for anticancer therapy.
Methods
Materials. DFP (ferriprox; 1,2-dimethyl-3-hydroxypyridin-4-one) was obtained
from Apo Pharma, and DHE was obtained from Sigma-Aldrich. The red
ﬂuorescent mitochondrial metal–sensor RPA was a kind gift from U. Rauen
and R. Sustmann, University of Duisburg-Essen, Essen, Germany. TMRE was
purchased from Molecular Probes. The Autophagy Antibody Kit was
obtained from Cell Signaling Technology. MCF-7 and MDA-MB-231 epithe-
lial breast cancer cells were obtained from American Type Culture Collection
(CRL-10317) and from Professor Tamar Peretz-Yablonski, Sharett Institute
of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem,
Israel, respectively.
Cell Culture and ShRNA Transfection.MDA-MB-231 cells were grown in 5%CO2
RPMI medium 1640 supplemented with 10% FCS, L- glutamine, and antibiotics
(Biological Industries). MCF7 cells were grown in complete DMEM (Life Tech-
nologies) supplemented with 10% FBS, 2 mM glutamine, 100 U/mL penicillin,
100 μg/mL streptomycin, and 0.25 μg/mL amphotericin B. Cells were main-
tained in 100-mm Petri dishes (Sarstedt) in an incubator (HERAcell 150i;
Thermo Scientiﬁc) controlled at 37 °C and 5% CO2. Cells were plated at 1 d be-
fore experimentation onto 12-well plates or onto microscopic slides glued to
perforated 3-cm-diameter tissue culture plates. Four unique 29-mer pGFP-V-
RS plasmid vectors were purchased from OriGene Technologies. The same
plasmid with a scrambled sequence cassette was used as a negative control.
Fig. 4. NAF-1 or mNT are required to support tumor growth. Breast cancer
cells (MDA-231) with or without suppressed expression of mNT (mNT−) or
NAF-1 (NAF-1−) were injected s.c. into the back of female CD1 nude mice,
and tumor growth was monitored over time. (A) Slower tumor growth of
breast cancer cells (MDA-231) with suppressed expression of mNT (mNT−) or
NAF-1 (NAF-1−) compared with control MDA-231 cells. (B) Reduction of
mean tumor volume expressed as percentage of control MDA-231 in mNT−
or NAF-1− MDA-231 cells. (C and D) Images of representative tumors of each
group obtained at the end of the experiment. (E) Histological analyses of
tumors using H&E staining showing large necrotic areas in tumors formed
from the control MDA-231 cells compared with tumors formed from mNT−
or NAF-1− MDA-231 cells. *P < 0.05.
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All shRNA transfections were performedwith 1 μg DNA using Lipofectamine
2000 (Invitrogen) or Genejuice (EMD Millipore) as a transfection reagent
according to themanufacturer’s instructions. Cells were treatedwith 1 μg/mLof
puromycin for 48 h. Transfection efﬁciency wasmonitored by the expression of
GFPat24h after transfection. Stableknockdown lines formNT (CISD1) andNAF-
1 (CISD2) were obtained by FACS after 3 mo of sorting based on GFP ﬂuores-
cence. The stable lines isolated were characterized for the level of the NEET
proteins in them by protein blots.
For autophagy protein blot analysis, control, mNT−, and NAF-1− cells were
grown to full conﬂuence. Medium was aspirated from cultures. Cells were
washed with 1× PBS and immediately scraped off the plate into a micro-
centrifuge tube and processed. Protein gels were loaded based on equal protein
levels and analyzed for autophagy markers according to the manufacturer’s
instructions (Cell Signaling Technology). For growth curve analysis, 1 mL of cells
were seeded in 24-well plates at 20,000 cells/well. Cells were counted using
a Moxi Z cell counter and S cassettes (ORFLO Technologies) every day for 6–10 d.
OCR and ECAR were measured using a Seahorse XF24 analyzer with the XF
Cell Mito Stress Test Kit and XF Glycolysis Stress Test Kit (Seahorse Bioscience),
according to the manufacturer’s instructions. In brief, cells were grown to
approximately 70–80% conﬂuence in complete DMEM, trypsinized, and
seeded in 100-μL volume at 80,000 cells per well in an XF24 cell culture
microplate. Cells were then incubated at 37 °C with 5% CO2 for 3 h. The
initial culture medium was exchanged, and the plates were incubated at 37 °C
without added CO2 for 1 h before the assay. Plates were then transferred to
the XF24 analyzer. The OCR was calculated after sequential additions of
oligomycin A, FCCP, antimycin A, and rotenone using an XF Cell Mito Stress
Test Kit. The ECAR was calculated after sequential additions of glucose,
oligomycin, and 2-DG using an XF Glycolysis Stress Test Kit. All measure-
ments were recorded at set interval time points. All compounds and mate-
rials were obtained from Seahorse Bioscience.
Microscopy. Cells were cultured in glass-bottomed microscope dishes and
analyzed using an epi-ﬂuorescent microscope with a confocal (quality
equivalent) opti-grid device (Nikon TE 2000 microscope equipped with
a thermostatted stage and a Hamamatsu Orca-Era CCD camera) and driven by
the Volocity 4 operating system (Improvision), which was used for both image
data acquisition and analysis (31). The mitochondrial labile iron pool was
measured by exposing cells for 15 min to 0.5 μM RPA, a mitochondrial-
speciﬁc ﬂuorescent probe that undergoes quenching on binding of iron.
Owing to the irreversible iron-binding afﬁnity of RPA, an iron chelator
pretreatment can provide an indirect determination of mitochondrial labile
iron level. Mitochondrial membrane potential (MMP) was measured micro-
scopically with TMRE using Texas Red (excitation, 543 nm; emission, 633 nm)
ﬁlter sets. Cell mitochondrial ROS production was determined by incubating
cells at 37 °C with 10 μM DHE, which displays blue ﬂuorescence in cell cy-
toplasm. The oxidized form (ethidium) of the probe was obtained by re-
action with ROS, which turns the probe ﬂuorescent red for microscopic
analysis (excitation, 518 nm; emission, 605 nm). Pretreatment of cells with
the chelator DFP (50–100 μM) was performed at indicated times.
Cell Viability and Metabolic Activity. Cell viability and metabolic activity were
determined as described previously (31). MCF-7 or MDA-231 cells in 12–well
culture plates were supplemented with Alamar blue reagent (10% vol/vol),
and ﬂuorescence was measured on a plate reader after 1–4 h of incubation
at 37 °C (excitation, 530–560 nm; emission, 590 nm).
Electron Microscopy and Morphometric Analysis of Mitochondrial Damage.
Cells were grown on eight-chamber slides to ∼70% conﬂuence and ﬁxed in
2.5% glutaraldeyde and 2% paraformaldehyde in 0.1 M cacodylate buffer (pH
7.4) for 2 h at room temperature. Cells were then rinsed four times for 10 min
each in cacodylate buffer, postﬁxed, and stained with 1% osmium tetroxide
and 1.5% potassium ferricyanide in 0.1 M cacodylate buffer for 1 h. Cells were
then washed four times in cacodylate buffer, followed by dehydration in in-
creasing concentrations of ethanol consisting of 30%, 50%, 70%, 80%, 90%,
and 95% for 15 min at each step, followed by 100% anhydrous ethanol three
times for 20 min each. After dehydration, the cells were inﬁltrated with in-
creasing concentrations of Agar 100 resin in ethanol, consisting of 25%, 50%,
75%, and 100% resin, for 16 h at each step. The cells were then embedded in
fresh resin and allowed to polymerize in an oven at 60 °C for 48 h. Embedded
cells in blocks were sectioned with a diamond knife on an LKB 3 microtome,
and ultrathin sections (80 nm) were collected onto 200-mesh, thin-bar copper
grids. The sections on grids were sequentially stained with uranyl acetate and
lead citrate for 10 min each and viewed with a Tecnai 12 100-kV transmission
electronmicroscope (FEI) equippedwithMegaView II CCD camera and Analysis
version 3.0 software (SoftImaging Systems). Quantitative analysis of mito-
chondrial damage was performed by two investigators, who independently
reviewed each enlarged electron microscopy image for the presence of
structurally abnormal mitochondria. Structurally abnormal mitochondria were
deﬁned operationally as those with loss of cristae and integrity of mitochon-
drial membrane and the formation of autophagosomes. The number of
damaged mitochondria per image was quantiﬁed and analyzed by ANOVA
using Origin 8.1 (OriginLab Corp.)
Animal Studies. All surgical and experimental procedures and animal care were
performed in accordance and compliance with the policies approved by the
HebrewUniversity administrativepanel on laboratory animal care (A. Hochberg
laboratory). Animals were kept at the Hebrew University’s animal facility, with
water and food ad librum. Histopathological examinations of the different
tumors were performed in consultation with a trained pathologist. Conﬂuent
MDA231 human breast carcinoma cells (control and shRNA stable lines of
mNT− and NAF-1−) were trypsinized to a single-cell suspension and resus-
pended in PBS. Then 2 × 106 cells (in 200 μL volume) were s.c. injected into the
backs of 6- to 8-wk-old female nonirradiated CD1 nude mice. At 7 d after cell
inoculation, the developing tumors were measured in two dimensions. The
mice were divided into different groups of the same size (n = 5) for each cell
line injected. Tumor dimensions were measured every week, and tumor areas
were calculated according to the formula width × length. The animals were
killed at 6.5 wk after the injections, after which the tumors were excised and
their ex vivo weight and volume measured. Samples of the tumors were
ﬁxed in 4% buffered formaldehyde and processed for histological exam-
ination for evidence of necrosis and tumor persistence.
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